Prasugrel, a Third-Generation P2Y12 Receptor Antagonist, in Patients With Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention
Why the study?
Does an adjusted dosing regimen of prasugrel reduce major cardiovascular events compared to clopidogrel in Japanese patients undergoing elective PCI?
Population
742 Japanese patients with coronary artery disease scheduled for elective percutaneous coronary intervention.
Comparison
Prasugrel vs Clopidogrel
Design
RCT, randomized, double-blind
Follow-up
24 to 48 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports adjusted-dose prasugrel over clopidogrel for elective PCI in Japanese patients; extends RCT evidence to this population and dosing.
Structured PICO
Does an adjusted dosing regimen of prasugrel reduce major cardiovascular events compared to clopidogrel in Japanese patients undergoing elective PCI?
P
Population
742 Japanese patients with coronary artery disease scheduled for elective percutaneous coronary intervention (coronary artery stenting).
I
Intervention
Prasugrel (20 mg loading dose, 3.75 mg maintenance dose)
C
Comparator
Clopidogrel (300 mg loading dose, 75 mg maintenance dose)
O
Outcome
Composite of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke) up to week 24composite
An adjusted-dose prasugrel regimen (20/3.75 mg) demonstrated a favorable efficacy and safety profile compared to standard clopidogrel in Japanese patients undergoing elective PCI.
Limitations
- Larger studies are required to confirm these findings
Cite This Study
Isshiki et al. (2014) studied this question.